CDK4 and interstitial lung disease: Therefore, during the use of CDK4/6 inhibitors, ILD should be closely monitored, and the importance of early recognition of signs/symptoms suggestive of ILD (e.g., dyspnea) should be strengthened, especially at the beginning of treatment.